Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab.
Hagel
Stefan
S
Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Loschgestrasse 8, 91054 Erlangen, Germany.
Jantsch
Jonathan
J
Budde
Ulrich
U
Kalden
Joachim R
JR
Eckardt
Kai-Uwe
KU
Veelken
Roland
R
D051722:ADAM Proteins / Q000276:immunology; D000071120:ADAMTS13 Protein; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies / Q000097:blood; D016913:Blood Component Transfusion; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D010976:Platelet Count; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D000069283:Rituximab; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human